Patents by Inventor Elfaith Elzein

Elfaith Elzein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Process for preparing an A-adenosine receptor agonist and its polymorphs
    Patent number: 8106183
    Abstract: Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.
    Type: Grant
    Filed: April 22, 2010
    Date of Patent: January 31, 2012
    Assignee: Gilead Sciences, Inc.
    Inventors: Jeff Zablocki, Elfaith Elzein
  • PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS
    Publication number: 20100267953
    Abstract: Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.
    Type: Application
    Filed: April 22, 2010
    Publication date: October 21, 2010
    Inventors: Jeff Zablocki, Elfaith Elzein
  • PROCESS FOR PREPARING AN A2A-ADENOSINE RECEPTOR AGONIST AND ITS POLYMORPHS
    Publication number: 20100179313
    Abstract: Disclosed is a synthesis suitable for large scale manufacture of an A2A-adenosine receptor agonist, and also relates to polymorphs of that compound, and to methods of isolating a specific polymorph.
    Type: Application
    Filed: January 13, 2010
    Publication date: July 15, 2010
    Inventors: Jeff Zablocki, Elfaith Elzein
  • A2B adenosine receptor antagonists
    Patent number: 6977300
    Abstract: Disclosed are novel A2B adenosine receptor antagonists having the structure of Formula I or Formula II: The compounds are particularly useful for treating asthma, inflammatory gastrointestinal tract disorders, cardiovascular diseases, neurological disorders, and diseases related to undesirable angiogenesis.
    Type: Grant
    Filed: May 6, 2003
    Date of Patent: December 20, 2005
    Assignee: CV Therapeutics, Inc.
    Inventors: Rao Kalla, Thao Perry, Elfaith Elzein, Vaibhav Varkhedkar, Xiaofen Li, Prabha Ibrahim, Venkata Palle, Dengming Xiao, Jeff Zablocki
  • Heteroaryl alkyl piperazine derivatives
    Patent number: 6849632
    Abstract: Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of diabetes, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
    Type: Grant
    Filed: December 5, 2002
    Date of Patent: February 1, 2005
    Assignee: CV Therapeutics, Inc.
    Inventors: Jeff Zablocki, Prabha Ibrahim, Kevin Shenk, Elfaith Elzein, Venkata Palle
  • Substituted alkylene diamine compounds
    Patent number: 6638970
    Abstract: Novel compounds of the general formula: and pharmaceutically acceptable acid addition salts thereof, wherein the compounds are useful in therapy to protect skeletal muscles against damage resulting from trauma or to protect skeletal muscles subsequent to muscle or systemic diseases such as intermittent claudication, to treat shock conditions, to preserve donor tissue and organs used in transplants, in the treatment of cardiovascular diseases including atrial and ventricular arrhythmias, Prinzmetal's (variant) angina, stable angina, and exercise induced angina, congestive heart disease, and myocardial infarction.
    Type: Grant
    Filed: February 22, 2001
    Date of Patent: October 28, 2003
    Assignee: CV Therapeutics, Inc.
    Inventors: Elfaith Elzein, Jeff Zablocki, Tim Marquart